Schizophrenic women with the APOE ∈4 allele have a worse prognosis than those without it

• Published in: Molecular psychiatry Vol. 6; no. 3; pp. 307 - 310
• Main Authors: MARTORELL, L, VIRGOS, C, VALERO, J, COLL, G, FIGUERA, L, JOVEN, J, POCOVI, M, LABAD, A, VILELLA, E
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.05.2001
• Subjects: Adult and adolescent clinical studies; Alzheimer's disease; Apolipoproteins; Biological and medical sciences; Gender differences; Genotype & phenotype; Hypotheses; Medical sciences; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychoses; Risk factors; Schizophrenia; Women; Spain; Psychosis; Human; Phenotype; Prognosis; Apolipoprotein E; Schizophrenia; Female
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/sj.mp.4000855

The epsilon 4 allele of APOE is generally accepted to be a risk factor in Alzheimer's disease and it has been related to other neuropsychiatric disorders, including schizophrenia. The results of several case-control studies have been inconclusive. To shed more light on this issue we carried out an association study that compared the APOE common variant in a group of 365 schizophrenia patients and 584 controls. We found no differences in the genotype distributions and allele frequencies of patients and controls. In the group of patients, we also analysed the possible influence of the epsilon 4 allele in the clinical variables. The most important findings are that the age at onset (AAO) of epsilon 4+ schizophrenic women, those that have one or two epsilon 4 alleles, is 4 years earlier than that of epsilon 4- women and their risk of suffering a negative syndrome subtype is four times greater. This was not found in schizophrenic men. Our results show that the APOE variant is not a risk factor for developing schizophrenia but that it may modulate its phenotypic expression in a sex-dependent manner.